Dental Plaque Clinical Trial
Official title:
Plaque Removal Efficacy of AutoBrush®, a 360 Degree Sonic Power Toothbrush in Children
Verified date | March 2024 |
Source | Lander Enterprises, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this single-use, examiner blinded, randomized, two-period, cross-over, IRB-approved clinical study is to evaluate the safety and plaque removal efficacy of AutoBrush®, a new children's 360° sonic toothbrush, compared to a marketed children's manual toothbrush.
Status | Completed |
Enrollment | 22 |
Est. completion date | February 17, 2023 |
Est. primary completion date | February 17, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 5 Years to 8 Years |
Eligibility | To be eligible for study participation, subjects must meet the following criteria: 1. Generally healthy males and females at least 5-8 years of age. 2. Volunteers provide assent to participate and consent from a parent or legal guardian prior to being enrolled into the study. 3. A minimum of 12 natural teeth with scorable facial and lingual surfaces. Partially erupted permanent teeth and primary teeth that are loose or in the process of exfoliation are not included in the tooth count. Teeth that ware grossly carious, orthodontically banded, exhibiting general cervical abrasion and/or enamel abrasion ware not included in the tooth count. 4. A plaque index score = 1.80 according to the Lobene-Soparkar Modification of the Turesky Modification of the Quigley-Hein Plaque Index, following 12 to 16 hours plaque accumulation Exclusion Criteria: Subjects presenting with any of the following will not be included in the study: 1. Having a history of adverse effects, oral soft or hard tissue sensitivity, to any ingredient in the test materials. 2. Having self-reported serious medical conditions. 3. Being under treatment for a heart condition requiring use of a pacemaker. 4. Having anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study. 5. Having had antibiotic, anti-inflammatory, anti-coagulant medication or chemotherapeutic antiplaque/antigingivitis therapy within 30 days of screening exams. 6. Having participated in any study involving oral care products, concurrently or within the 30 days of screening exams. 7. Presence of severe periodontal disease or being actively treated for periodontal disease. 8. Having grossly carious, fully crowned, or extensively restored teeth. 9. Having orthodontic appliances, peri/oral piercings, or removable partial dentures. 10. Having significant oral soft tissue pathology based on a visual examination. |
Country | Name | City | State |
---|---|---|---|
United States | Salus Research, Inc | Fort Wayne | Indiana |
Lead Sponsor | Collaborator |
---|---|
Lander Enterprises, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Within-Treatment Whole-Mouth Differences (vs Baseline) - Plaque removal Mean Change from baseline (pre-brushing to post-brushing) in plaque score after single supervised use based on all tooth surfaces of the whole mouth. | Supragingival dental plaque: Lobene-Soparkar Modification of Turesky Modification of Quigley-Hein Plaque Index
Plaque will be disclosed using a red disclosing solution and each tooth will be scored in six areas (disto-buccal, mid-buccal and mesio-buccal, disto-lingual, mid-lingual and mesio-lingual), according to the criteria noted below: 0 = No plaque. = Separate flecks or discontinuous band of plaque at the gingival (cervical) margin. = Thin (up to 1 mm), continuous band of plaque at the gingival margin. = Band of plaque wider than 1 mm but less than 1/3 of tooth surface area. = Plaque covering 1/3 or more, but less than 2/3 of tooth surface area. = Plaque covering 2/3 or more of tooth surface area. |
Up to 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04881357 -
Antiplaque/Antigingivitis Effect of Lacer Oros Integral
|
N/A | |
Completed |
NCT04561960 -
Efficacy of Miswak in Oral Hygiene Maintenance
|
Phase 4 | |
Completed |
NCT04025684 -
Efficacy of Manual Toothbrushes in Removing Dental Plaque
|
N/A | |
Completed |
NCT03394729 -
Effect of a Propolis Tablet on the Saliva and the Amount of Adolescent Dental Plaque Microbes
|
Phase 2/Phase 3 | |
Completed |
NCT05187507 -
Effectiveness of Theobromine Toothpaste
|
N/A | |
Completed |
NCT04485520 -
Efficacy of the Extract of Carica Papaya as an Inhibitor of Streptococcus Mutans
|
N/A | |
Completed |
NCT02884817 -
Essential Oil+ELA, Plaque and Gingivitis
|
Phase 4 | |
Completed |
NCT02552589 -
Effect of Toothpaste on the Reduction of Plaque and Inflammation
|
N/A | |
Completed |
NCT02194023 -
Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.
|
Phase 2 | |
Completed |
NCT01237782 -
Efficacy of a Propolis-based Denture Cleanser
|
N/A | |
Completed |
NCT00758394 -
Clinical Study to Compare Dental Plaque Control
|
Phase 3 | |
Completed |
NCT00254345 -
Effect of Provisional-Crown Surface Coating on Biofilm Formation
|
Phase 1 | |
Completed |
NCT05579938 -
Effect of Enzymes on Dental Biofilm Accumulation
|
N/A | |
Completed |
NCT05038293 -
Efficacy of Plaque Removal of a Novel Brushing Device
|
N/A | |
Terminated |
NCT05082103 -
Effect of Enzymes on Dental Biofilm Accumulation in Healthy Individuals
|
N/A | |
Not yet recruiting |
NCT06081868 -
RCT on Effectiveness of Oral Health Preventive Programmes in School Children in Uganda
|
N/A | |
Completed |
NCT05853679 -
Regular Antibacterial Photodynamic Therapy on Oral Hygiene in Elderly Residents
|
N/A | |
Completed |
NCT05521230 -
Short-Term Anti-plaque Effect of Cymenol Mouthwash Analysed Using Dentius Deep Plaque Software
|
Phase 1 | |
Completed |
NCT03311438 -
Oral Health Intervention Program for Children With Congenital Heart Defects
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A |